Sort   by:  
 Page size 
ProteomicsProteomics to determine metallodrug targets and optimal drug combinations
The FITExP profiling approach was used to identify protein hits from cells incubated with RAPTA-T or RAPTA-EA. Validation experiments with paclitaxel and cisplatin underlined the reliability of the method and hit lists for both test compounds (and?) gave physiologically viable anti-cancer mechanisms...
ORGANISM(S): Homo sapiens (Human) 
2018-02-09 | PXD005766 | Pride
Drug targets Fitexp Cancer 
UnknownExpression proteomics study to determine metallodrug targets and optimal drug combinations.
Not available
S-EPMC5431558 | biostudies-literature
ProteomicsComprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than Auranofin
Anticancer drugs that target cellular antioxidant systems have recently attracted much attention. Auranofin (AF) is currently evaluated in several clinical trials as an anticancer agent and targets the cytosolic and mitochondrial forms of the selenoprotein thioredoxin reductase, Txnrd1 and Txnrd2. R...
ORGANISM(S): Mus musculus (Mouse) 
2021-12-15 | PXD028398 | Pride
Inhibition Thioredoxin reductase Cancer Proteomics Mouse 
ProteomicsProTargetMiner: A proteome library of anticancer molecules for functional discovery
As a further development of our Functional Identification of drug Targets by Expression Proteomics (FITExP) method, a reference dataset was built of the proteomic responses of A549 human adenocarcinoma cells to 56 clinical and experimental anticancer molecules. For each molecule, a concentration was...
ORGANISM(S): Homo sapiens (Human) 
2019-11-01 | PXD009775 | Pride
Cancer Drug Proteomics Mass spectrometry A549 Resource Expression Chemotherapeutic Database Compound 
ProteomicsProTargetMiner: A proteome library of anticancer molecules for functional discovery
As a further development of our Functional Identification of drug Targets by Expression Proteomics (FITExP) method, a reference dataset was built of the proteomic responses of A549 human adenocarcinoma cells to 56 clinical and experimental anticancer molecules. For each molecule, a concentration was...
ORGANISM(S): Homo sapiens (Human) 
2019-11-01 | PXD009644 | Pride
Cancer Drug Proteomics Mass spectrometry A549 Resource Expression Chemotherapeutic Database Compound 
ProteomicsComprehensive chemical proteomics for target deconvolution of the redox active drug auranofin
Chemical proteomics encompasses novel drug target deconvolution methods in which compound modification is not required. Herein we use Thermal Proteome Profiling, Functional Identification of Target by Expression Proteomics and multiplexed redox proteomics for deconvolution of auranofin targets to ai...
ORGANISM(S): Homo sapiens (Human) 
2020-03-19 | PXD016776 | Pride
Cancer Nfkb2 Mass spectrometry Hct116 Thioredoxin reductase Expression Chordc1 Database A375 Drug Proteomics Resource Rko Chemotherapeutic Auranofin Compound 
ProteomicsDynamic proteomics reveals unexpected plasticity of cellular proteome: growth-related and drug-induced changes in cancer cells are comparable
In proteomics, the changes occurring in cellular proteomes upon drug treatment are used to identify the drug targets and the mechanism of action. However, proteomes of cultured cells undergo also natural alteration associated with changes in the media, attaining a degree of confluence as well as due...
ORGANISM(S): Homo sapiens (Human) 
2018-11-07 | PXD007762 | Pride
Fitexp  mass spectrometry  proteomics  principal component analysis  time series 
ProteomicsAnticancer effect of deuterium depleted water - comprehensive proteomics analysis suggests a redox disbalance mechanism
The proteomics data is derived from 4 parts of samples prepared and analysed by nanoLC-MS/MS. In order to make appropriate statistical analysed could be performed, all treatments were performed in biological replicates. The number of replicates was 4 for protein abundances analysis (part 1), 2 for t...
ORGANISM(S): Homo sapiens (Human) 
2019-09-26 | PXD011085 | Pride
Anticancer Proteomics Redox disbalance Deuterium depleted water 
Sort   by:  
 Page size